Work

A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.tps424

Authors: Nabil Adra, David J. Vaughn, Lawrence Einhorn, Nasser H. Hanna, Matt Rosales, Ahsan Arozullah, Darren R. Feldman

Institutions: Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Abramson Cancer Center, University of Pennsylvania, Astellas Pharma (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Testicular diseases and treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Astellas Pharma US

OpenAlex ID: W3008469154

Cites:

Cited by: 5

Related to: 10